AIT-082 Phase 1B Study

Completed · Phase 1

Conditions studied: Memory Disorders

In brief

AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits. This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.

Key facts

Study ID

NCT00000180

Run by

National Institute on Aging (NIA)

Expected to finish

2005-06-01

Last updated by the study team

2009-12-11

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

Where it is running

• University of California, San Diego — San Diego, California, United States
• Indiana University Alzheimer's Center — Indianapolis, Indiana, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Washington University — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.